Consensus Enlivex

Stocks

ENLV

IL0011319527

Market Closed - Nasdaq 21:30:00 18/09/2026 BST			5-day change	1st Jan Change
0.8066 ^USD	+10.92%		-15.94%	-92.35%

07-28	Enlivex Ltd. announced that it expects to receive $400 million in funding	CI
07-13	Enlivex Receives FDA Regenerative Medicine Advanced Therapy Designation for Allocetra in Age-Related Knee Osteoarthritis	CI

Evolution of the Average Target: Enlivex

Evolution of the Target Price: Enlivex

Changes in Analyst Recommendations: Enlivex

9cf962ba454cfd.DUQQkYbFThnfPMKhJtlOzLjEgbGKhsIUq2H32U5UsM4.RSZg5OPwJU6neouVd5x3o-j99tPz1Icm-SuWgz0LwINGFiXpq4gDfO1_qQ~9f41b7837640e80f9cda71696177243a

Analysts' recommendations: Enlivex

11/06/24	HC Wainwright Adjusts Price Target on Enlivex Therapeutics to $6 From $7, Maintains Buy Rating	MT
12/04/24	HC Wainwright Adjusts Enlivex Therapeutics Price Target to $7 From $12, Maintains Buy Rating	MT
25/09/23	HC Wainwright Cuts Enlivex Therapeutics Price Target to $12 From $15, Maintains Buy Rating	MT
02/05/22	HC Wainwright Adjusts Enlivex Therapeutics' Price Target to $15 from $33, Keeps Buy Rating	MT

More recommendations

Analysts' Consensus

Sell

Consensus

Buy

Mean consensus

BUY

Number of Analysts

1

Last Close Price

0.8066USD

Average target price

80.00USD

Spread / Average Target

+9,818.18%

High Price Target

80.00USD

Spread / Highest target

+9,818.18%

Low Price Target

80.00USD

Spread / Lowest Target

+9,818.18%

Analyst Consensus Detail

Consensus revision (last 18 months)

Stock Market
Stocks
ENLV Stock
Consensus Enlivex

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!

SEIZE THE OFFER!